Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vicks Sinex recalls in U.S., Europe

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble voluntarily recalls three lots of Vicks Sinex 15-mL nasal sprays marketed in Germany, the U.K. and the U.S. after finding the bacteria B. cepacia in products made at its facility in Gross Gerau, Germany. The firm says the recall is precautionary and no illnesses are reported, but the bacteria could cause serious infections for people with a compromised immune system or those with chronic lung conditions. P&G detected the bacteria during routine quality control testing and said analysis shows the problem is limited to a single batch of raw material mixture involving these lots: 9239028831 - Vapospray 12-Hour Decongestant Ultra Fine Mist in the U.S.; 9224028832 - Micromist Aqueous in the U.K.; and 9224028833 - Wick Sinex Schnupfenspray Dosiersystem in Germany

You may also be interested in...



P&G recalls Vicks product sans child-resistant packaging

Procter & Gamble recalls bonus packs of Vicks DayQuil Cold & Flu 24-Count LiquiCaps that lack child-resistant blister-pack backing. While otherwise safe for patients aged 12 and older, the product is labeled as having child-resistant packaging, the firm said Dec. 18. P&G recently recalled multiple lots of Vicks Sinex 15-mL nasal spray products due to possible bacterial contamination (1"The Tan Sheet" Nov. 23, 2009, In Brief)

US FDA Connects Dots For Drug Manufacturers’ Responses To CRLs With Draft Guidance

CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.

Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel